MOUD Naltrexone LA denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for moud naltrexone la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Long-Acting Naltrexone as Experimental — and Why That Classification Is Wrong

An experimental or investigational denial for long-acting injectable naltrexone for opioid use disorder is a factual error. The FDA granted full approval for this product for the treatment of OUD in adults following detoxification. It is not a clinical trial drug, not a compounded formulation, and not an off-label use when prescribed for its approved indication. An experimental classification for a fully FDA-approved drug used for its labeled indication is a reversible denial.

## Why This Denial Is Appealable

Insurers' experimental/investigational exclusions are defined in plan documents — and those definitions almost universally require that the drug lack FDA approval for the relevant indication, or that the evidence base be insufficient for clinical use. Long-acting injectable naltrexone satisfies neither of those conditions. The FDA-approved prescribing label is definitive proof that the experimental classification is inapplicable.

Federal parity law (MHPAEA) adds a second layer: if Cigna covers other FDA-approved chronic-disease maintenance medications without an experimental designation, applying that designation selectively to an FDA-approved OUD medication is a potential parity violation.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal immediately, attaching the FDA prescribing label as the primary evidence. The appeal deadline is on the denial letter — do not miss it.
• External review: After exhausting internal review (or if Cigna misses its decision deadline), request independent external review under ACA §2719. The window is generally up to four months from the internal denial notice. An external reviewer who sees the FDA approval documentation will find the denial unsupported.
• Expedited appeal: If the patient is at acute risk without access to the medication, the prescriber can request an expedited determination, typically resolved within 72 hours.

## Concrete Appeal Steps

1. Obtain the full denial letter and locate the exact experimental/investigational policy language Cigna applied. 2. Download the FDA prescribing label for the product from Drugs@FDA — this is your core evidence document. 3. Pull Cigna's coverage policy and locate their definition of experimental/investigational. Confirm that long-acting naltrexone does not meet any element of that definition for the OUD indication. 4. Have the prescriber write a letter citing the FDA approval and documenting the diagnosis, confirming this is an approved use. 5. Submit the internal appeal. If denied again, proceed immediately to external review.

## Documentation to Gather

• FDA prescribing label: From Drugs@FDA, showing the product's approval and labeled indication for OUD.
• Diagnosis confirmation: DSM-5 OUD diagnosis matching the FDA-labeled indication.
• Prescriber letter: Confirming the approved indication, referencing applicable ASAM/SAMHSA clinical guidelines by organization name, and explicitly rebutting the experimental classification by citing the FDA label.
• Parity documentation (if applicable): If Cigna covers other FDA-approved chronic-condition medications without experimental review, document that asymmetry.
• Criteria-mapping table: Each element of Cigna's experimental definition in one column; the counter-evidence (primarily the FDA label) in the adjacent column.

## Criteria-Mapping Structure

Experimental-denial appeals are documentation-intensive but logically straightforward: the entire structure rests on demonstrating that the drug is FDA-approved for the specific indication being treated. Use the criteria-mapping table to walk through each element of Cigna's definition and show it is not met. Keep the letter factual and concise — the FDA label does the heavy lifting.